Product Licensing
License, asset purchase agreement with VivoQuest for intellectual property and technology announced
Published in AIDS Weekly, October 24th, 2005
Following the closing of these agreements, XTLbio has an exclusive license to VivoQuest's intellectual property and technology, including promising hepatitis C virus (HCV) compounds and VivoQuest's proprietary compound library.
In connection with the closing, XTL Biopharmaceuticals (XTLbio) made an up-front payment of approximately $1.4 million, which was satisfied through the issuance to VivoQuest of approximately 1.3 million XTLbio ordinary shares. All other amounts to be paid to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-10-24)
More Articles from AIDS Weekly
- HIV/AIDS Diagnostics
CD4% values in HIV-infected children are unreliable due to measurement error - HIV/AIDS Diagnostics
High sequence homology indicates HIV genotyping assay proficiency - HIV/AIDS Immunity
Low-level antigen exposure is sufficient for sustained HIV-specific immunity - HIV/AIDS Transmission
Cervicovaginal culture system determines HIV transmission events after exposure - HIV/AIDS Transmission
Immunophenotyping helps predicts risk of perinatal HIV transmission - Adverse Drug Reaction
Drugs raise mitochondrial toxicity risk in HIV/hepatitis C-coinfected patients - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
